149 related articles for article (PubMed ID: 32274219)
1. Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab.
Cuenca JA; Laserna A; Reyes MP; Nates JL; Botz GH
Case Rep Crit Care; 2020; 2020():8671530. PubMed ID: 32274219
[TBL] [Abstract][Full Text] [Related]
2. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.
Kusuki K; Suzuki S; Mizuno Y
Endocrinol Diabetes Metab Case Rep; 2020 Apr; 2020():. PubMed ID: 32478673
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
[TBL] [Abstract][Full Text] [Related]
5. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S
Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188
[TBL] [Abstract][Full Text] [Related]
6. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy.
Hernandez A; Zeidan B; Desai P; Frunzi J
Cureus; 2021 Feb; 13(2):e13302. PubMed ID: 33738153
[TBL] [Abstract][Full Text] [Related]
8. New-onset insulin-dependent diabetes due to nivolumab.
Zaied AA; Akturk HK; Joseph RW; Lee AS
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29623210
[TBL] [Abstract][Full Text] [Related]
9. A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma.
Salangsang J; Sapkota S; Kharel S; Gupta P; Kalla A
Cureus; 2023 Feb; 15(2):e35276. PubMed ID: 36825072
[TBL] [Abstract][Full Text] [Related]
10. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma.
Wu L; Li B
Diabetes Metab Syndr Obes; 2021; 14():753-757. PubMed ID: 33628041
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: A case report.
Li S; Zhang Y; Sun Z; Hu J; Fang C
Medicine (Baltimore); 2018 Nov; 97(45):e12907. PubMed ID: 30407284
[TBL] [Abstract][Full Text] [Related]
13. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
Mae S; Kuriyama A; Tachibana H
J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab-induced type 1 diabetes.
Maia A; Soares DM; Azevedo S; Pereira T; Amaral C
J Oncol Pharm Pract; 2024 May; ():10781552241255699. PubMed ID: 38766907
[TBL] [Abstract][Full Text] [Related]
15. Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab.
Chokr N; Farooq H; Guadalupe E
Case Rep Oncol Med; 2018; 2018():8981375. PubMed ID: 29623227
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy.
Alrifai T; Ali FS; Saleem S; Ruiz DCM; Rifai D; Younas S; Qureshi F
Case Rep Oncol Med; 2019; 2019():8781347. PubMed ID: 31781446
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
18. Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy.
Keerty D; Das M; Hallanger-Johnson J; Haynes E
Cureus; 2020 Sep; 12(9):e10632. PubMed ID: 33123445
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune Diabetes Presented with Diabetic Ketoacidosis Induced by Immunotherapy in an Adult with Melanoma.
Alzenaidi AA; Dendy J; Rejjal L
J La State Med Soc; 2017; 169(2):49. PubMed ID: 28414668
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
Aleksova J; Lau PK; Soldatos G; McArthur G
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27881588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
